Chen JJ, Zhu RS, Zhou JP, Yang TW, Zhang X, Xu MJ, Rao ZM
BPC-157 is widely discussed in preclinical research as a stable gastric pentadecapeptide used in experimental models that probe tissue response, inflammation signaling, vascular and extracellular matrix dynamics, and gastrointestinal barrier related questions
To elucidate which proteins are susceptible to carbonylation in -cells in T1D settings, we recently mapped over 1000 individual carbonylated proteins in islets from pre-diabetic NOD mice side by side with MIN6 -cells treated with 4-HNE or cytokines ( Table 1 ), including, Sec61 translocon subunit alpha 1 (SEC61A1), ADP ribosylation factor 1 and 3 (ARF1, 3), RAB3 GTPase activating protein catalytic subunit 1 (RAB3GAP1), N ethylmaleimide sensitive factor (NSF), RAB18, member RAS oncogene family (RAB18), Syntaxin binding protein 1 (MUNC18-1), RAB7A, member RAS oncogene family (RAB7A), Syntaxin 5 (STX5), Adaptor related protein complex 2 subunit alpha 2 (AP2A2), Endoplasmic reticulum Golgi intermediate compartment 1 (ERGIC1), Dynamin 1 like (DNM1L), Transmembrane p24 trafficking protein 10 (TMED10), Post GPI attachment to proteins 1 (PGAP1) and JNK interacting protein 4 (JIP4) (182), we observed insulin (INS2) carbonylation upon exposure to 4-HNE (183)
And of course they can help you evaluate whether you need to do anything other than wait for it to go away and take pain med
